Project: Synergistic platform for the identification of small molecule drug leads for cancer immunotherapy

Develop, implement and commercialize an innovative drug discovery platform to identify small molecule compounds that modulate the activity of hallmark proteins in cancer that are difficult to drug. To obtain proof-of-principle, two key enzymes involved in the regulation of the body’s immune response against cancer cells will be screened by DNA-encoded small molecule compound libraries. Hits will subsequently be optimised to leads or pre-clinical candidates and out-licensed to pharma companies.

Acronym	ImmunoTherapyScreen (Reference Number: 9617)
Duration	01/07/2015 - 01/07/2017
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 3

Project partner

Number	Name	Role	Country
21087	Netherlands Translational Research Center B.V.	Coordinator	Netherlands
21088	Vipergen ApS	Partner	Denmark